CombiGene: "We continue to believe in the epilepsy project CG01"

CombiGene has regained the global rights to the epilepsy project CG01 from Spark Therapeutics after the collaboration agreement was terminated last year. BioStock reached out to CombiGene's CEO, Peter Ekolind, for a comment on the plans to continue the project.

Read the interview with Peter Ekolind at biostock.se:

CombiGene: "We continue to believe in the epilepsy project CG01" - BioStock

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/en/